HealthTree Podcast for Multiple Myeloma
HealthTree Podcast for MM
Subscribe
HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.
Available episodes
Newest first
Oldest first
4 days ago
Understanding Blood-Based Testing in Multiple Myeloma with Ola Landgren, MD, PhD
A wave of blood-based tests are being researched for myeloma care, and for good reason. Patients love the idea of replacing the painful bone marrow biopsy with a blood-based test, especially if it is equally effective. In addition to being less time consuming and painful, blood-based testing could be performed more regularly to provide more information to patients and their doctors.
The types of test vary. They include mass spectometry testing, blood-based MRD testing and circulating tumor cell testing. Many of these tools are still only used in research, but they are getting closer to being used in the myeloma clinic. Each of the tests have unique ways of providing a less invasive way of testing for myeloma at diagnosis and after treatment.
Ola Landgren, MD, PhD of the University of Miami Sylvester Cancer Center joins HealthTree Podcast for Multiple Myeloma to review the different types of tests, how they function, what they measure, pros and cons of each and how they are and could be used in regular myeloma practice.
As we continue to see these tests advance, it's a great idea to start becoming more familiar with the test types, test names and reasons for their use.
Thanks to our episode sponsor, GSK
playlist_add
Feb 1, 2023
A New "Moda" Targeting CD38 in Multiple Myeloma with Noa Biran, MD, John Theurer
Dr. Noa Biran of Hackensack University joins HealthTree Podcast for Multiple Myeloma to discuss a completely new approach targeting CD38, which is found on most myeloma cells. The drug called modafakusp alpha (formerly known as TAK-573) uses a new method of targeting CD38 by combining a monoclonal antibody with interferon. Early trial results are showing that this treatment option could also work for patients who relapsed after anti-CD38 monoclonal antibodies like daratumumab and isatuximab.
Inteferon is a human hormone that has been previously used in myeloma care because it can both kill the myeloma cells directly and engage the immune system to fight the myeloma, but it had many intolerable side effects. In this new form combined with modafakusp alpha, the side effects are significantly reduced. This new drug is now in clinical trials being tested with common myeloma therapies like dexamethasone, daratumumab, proteasome inhibitors and immunomodulators. Learn about this new treatment option in this informative show.
Having new treatment options, especially after patients have relapsed after the three most common drug classes (proteasome inhibitors, immunomodulators and anti-CD38 monoclonal antibodies) is a blessing for relapsed or refractory patients.
playlist_add
Jan 17, 2023
Myeloma Innovations in 2023 - An Annual Review with Robert Orlowski, MD, PhD
There are significant advances being made in multiple myeloma and more so than in any other cancer. Join us for this annual show with Robert Orlowski, MD, PhD as we discuss the recent findings from the American Society of Hematology (ASH) meeting, key innovations being developed in myeloma and what patients can expect to see in 2023. The show will review immunotherapy options, optimal combination therapies, targeted treatments and key learnings from top myeloma investigators.
Thanks to our episode sponsor, GSK
playlist_add
Nov 14, 2022
HealthTree Podcast for Multiple Myeloma: Teclistamab's Approval with Dr. Garfall
Teclistamab is the first bispecific antibody to be FDA approved in mulitple myeloma. On this HealthTree Podcast for Multiple Myeloma episode, learn from Alfred Garfall, MD of the University of Pennsylvania about how it will be used in the clinic as an approved therapy. Our discussion will include who qualifies for this new treatments, when patients should consider using it, if it can be combined with other myeloma therapies, if the therapy is continuous or can be stopped, common side effects to expect, how it is administered (in and outpatient) and how the caregiver needs to be involved.
playlist_add
Oct 31, 2022
HealthTree Podcast: Kidney Disease and Multiple Myeloma with Natalie Callander
Over 40% of multiple myeloma patients deal with kidney disease during their multiple myeloma journey. Learn more from Natalie Callander, MD of the University of Wisconsin at Madison about how myeloma affects the kidneys, what else causes kidney damage, signs and symptoms to watch for, tips to protect the kidneys, how to resolve kidney concerns, how dialysis plays a part in care and when a patient may need a kidney transplant.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
Oct 21, 2022
HealthTree Podcast for Myeloma: Ashraf Badros, MD, University of Maryland
Maintenance therapy over the past several years has commonly included the use of Revlimid (lenalidomide) over a long period of time. Is more better? Does more maintenance therapy or certain combinations help extend remissions or help patients deepen their responses?
Ashraf Badros, MD, of the University of Maryland will join the HealthTree Podcast for Multiple Myeloma to talk with us about the rationale behind the AURIGA clinical trial using daratumumab and lenalidomide following stem cell transplant for patients who are still MRD positive.
Myeloma experts are working to identify more personalized approaches for each type of myeloma patient. We know that patients who are still MRD positive following high dose therapy are more likely to have shorter remissions and the use of a different maintenance therapy may help patients who aren't getting their deepest responses do better over time.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
Jul 18, 2022
HealthTree Podcast for Multiple Myeloma: Paul Richardson, MD, Dana Farber
Myeloma advancements are happening quickly. Learn more from Paul Richardson, MD of the Dana Farber Cancer Institute about the latest findings from two key summer conferences.
Thanks to our episode sponsor, Glaxo Smith Kline
playlist_add
Jun 27, 2022
HealthTree Podcast for Myeloma: Jesus Berdeja, MD, Sarah Cannon on Allo CAR T
CAR T therapies are expanding as multiple myeloma treatment options. In addition to the two currently FDA approved CAR T therapies (Abecma and Carvykti) which use a patient's own T cells in a production process, new allo (off-the-shelf) options are being developed in clinical trials. Dr. Jesus Berdeja is one of the leading CAR T experts in multiple myeloma and in this episode, he will share the current development taking place for allo CAR T therapies. Join us to learn more about this exciting field in myeloma research which may provide faster and more availalble treatment options for patients.
Note: Myeloma Crowd Radio is becoming HealthTree Podcast for Multiple Myeloma.
playlist_add
Feb 7, 2022
HealthTree Podcast for Multiple Myeloma: Dr. Robert Orlowski on Myeloma in 2022
Dr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2022. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2022, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show.
Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including the Leukemia & Lymphoma Society Scholar in Clinical Research, the Leukemia & Lymphoma Society’s Man of the Year Award, Emil Frei III Award for Excellence in Translational Research from MD Anderson and is the recipient of an ongoing SPORE grant from the NIH. Find news and information from his daily newspaper, Myeloma Daily or find him on Twitter at @myeloma_doc.
Thanks to our episode sponsor, Bristol Myers Squibb
playlist_add
Jan 6, 2022
HealthTree Podcast for Myeloma: Shaji Kumar, MD, Mayo Clinic on ETBs in Myeloma
A new approach in myeloma immunotherapies is in the works called Engineered Toxic Bodies (ETBs). Early on, Molecular Templates partnered with Takeda Oncology to begin development on an ETB therapy for multiple myeloma targeting CD38. Currently, Molecular Templates is moving this therapy forward. ETBs work differently from monoclonal antibodies because they move deep inside the plasma cell instead of flagging the cell's surface. They also don't rely on the body's own immune system (like T cells or NK cells) to kill myeloma. Learn more about this emerging therapy from Dr. Shaji Kumar on this fascinating program.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
Jan 5, 2022
HealthTree Podcast: Dan Vogl, MD, UPENN and Yulia Nefedova, MD, PhD, Wistar
Join Dr. Dan Vogl and Dr. Yulia Nefedova to understand more about a new oral treatment for multiple myeloma called tasquinimod. This is a treatment that targets the tumor microenvironment by targeting myeloid-derived suppressor cells (MDSCs). MDSCs are a variety of cells that expand during cancer, inflammation and infection, and can suppress T-cell responses. They can stop myeloma killing-immune cells and at the same time form new tumor blood vessels that help myeloma spread in the body. The researchers are hopeful that tasquinimod will promote anti-tumor immune activity .
The treament is being developed by a Swedish company called Active Biotech and tasquinimod is now being tested in combination with standard myeloma therapies like lenalidomide, ixazomib and dex.
New treatments like these could be used in patients who have relapsed after standard myeloma treatment like daratumumab and could help alter the microenvironment that is causing myeloma relapse.
Thanks to our episode…
playlist_add
Oct 27, 2021
HealthTree Podcast for Multiple Myeloma: Elisabet Manasanch, MD, MD Anderson
Smoldering myeloma is a precursor condition for the blood cancer multiple myeloma. There is hot debate about when and how to treat this precursor condition. Do you treat it like regular myeloma? Do you try to prevent progression? And if so, with which therapies? Dr. Elisabet Manasanch of the MD Anderson Cancer Center provides an update on treatment in smoldering myeloma and smoldering myeloma clinical trial designs that seek to determine the very best approach.
Thanks to our episode sponsor, Bristol Myers Squibb
playlist_add
Oct 4, 2021
HealthTree Podcast: Cristina Gasparetto, MD Duke University & Mark Newman, OD
All cancer therapies come with some type of side effect. One newly approved therapy called BLENREP, by GSK, is an antibody drug conjugate targeting BCMA that can cause a condition called keratopathy. Keratopathy is an eye condition that can be mild, so patients don't even know they have it, or it can be more severe. Myeloma specialist Dr. Cristina Gasparetto, MD from Duke University and Mark Newman, OD of OPTIX Eye Center will share in this show how keratopathy can be successfully managed for patients on BLENREP. Learn what keratopathy is, how care is coordinated between the myeloma doctor and the eye doctor, and what patients should know about keratopathy before starting on this therapy.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
May 18, 2021
HealthTree Podcast for Myeloma: Peter Voorhees, MD, Levine Cancer Institute
Myeloma experts are beginning to use antibodies in earlier lines of myeloma treatment, even for newly diagnosed patients. Learn what recent clinical trials are using antibody therapies such as daratumumab and isatuximab in early quad (four) drug combinations for newly diagnosed patients. Peter Voorhees of the Levine Cancer Institute joins Myeloma Crowd Radio to share his experience and findings from these clinical trials. He will discuss the early use and their use as maintenance therapy following stem cell transplant. Is earlier use better? Should they be "saved" for later? When should patients consider using the monoclonal antibodies as maintenance therapy with or without traditional drugs like lenalidomide? Dr. Voorhees will help answer these very practical questions for the myeloma community.
Thanks to our episode sponsor, Karyopharm Therapeutics.
playlist_add
May 14, 2021
HealthTree Podcast for Myeloma: Sascha Tuchman, MD, University of North Carolina
AL Amyloidosis is a secondary condition that can occur in patients with multiple myeloma and can cause protein buildup in organs like the heart, kidneys, liver and nerves. Join HealthTree Podcast for Multiple Myeloma by HealthTree to hear from Sascha Tuchman, MD of the University of North Carolina at Chapel Hill as he shares amyloidosis symptoms, treatments and open clinical trials.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
Apr 16, 2021
HealthTree Podcast for Multiple Myeloma: Noopur Raje, MD, Mass General
CAR T therapy has been in development for over 20 years. The first CAR T therapy is now available for the treatment of multiple myeloma. The ide-cel treatment (now called Abecma) is now FDA approved for multiple myeloma relapsed or refractory patients. In this show, Dr. Noopur Raje of Mass General Hospital will share how the CAR T cell therapy works, outcome data from clinical trials, a review of patients who are eligible to join and when patients should consider the therapy in context of other therapies. Ide-cel (Abecma) is a product developed by Bristol Myers Squibb and blubird bio.
Thanks to our episode sponsor, Oncopeptides
playlist_add
Jan 22, 2021
HealthTree Podcast: Robert Z. Orlowski, MD, PhD, MD Anderson Myeloma in 2021
Dr. Robert Z. Orlowski joins HealthTree Podcast for Multiple Myeloma to share a study to share the new innovations myeloma patients can expect in 2021. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2021, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show.
Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provide…
playlist_add
Dec 16, 2020
HealthTree Podcast for Myeloma: Irene Ghobrial, MD, Dana Farber Cancer Institute
Dr. Irene Ghobrial joins HealthTree Podcast for Multiple Myeloma to share a study to identify discoveries that could potentially inform COVID-19 treatment decisions and prevention policies in the IMPACT study. Myeloma patients are known to be immunocompromised and may be at higher risk for poor outcomes.
IMPACT is a study to identify the prevalence and unique characteristics of COVID-19 in individuals with precursor conditions to hematologic malignancies and in healthy populations. It is enrolling individuals nationwide who are enrolled in the PCROWD and PROMISE studies.
All participants enrolled in IMPACT are screened using a blood test for active SARS-CoV-2 and/or antibodies. Participants are then followed and undergo additional blood collection and testing over a one-year period. The overall goal of IMPACT is to understand the short- and long-term impact of COVID-19 on the immune system of healthy individuals and individuals with underlying immune dysregulation.
Thanks…
playlist_add
Nov 6, 2020
HealthTree Podcast for Myeloma: Joshua Richter, MD, Mount Sinai COVID update
The coronavirus continues to be a global concern for all citizens and especially for cancer patients. Where are we at now with our learning over the last seven months? Dr. Joshua Richter re-joins HealthTree Podcast for Multiple Myeloma for an update on how myeloma patients are and should be navigating during the coronavirus pandemic.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
Oct 23, 2020
HealthTree Podcast: Jonathan Kaufman, MD, Emory University Winship Cancer Inst.
Venetoclax (Venclexta) is being studied in myeloma clinical trials and particular benefit has been seen in 11;14 myeloma patients. It is the first time a true precision medicine drug has been identified in myeloma. Which clinical trial combinations are using venetoclax, which are proving to be the most effective and is it getting closer to approval? Learn about the experiences of its use in 11;14 multiple myeloma patients and clinical trial results outside of this specific patient group. The innovation happening in myeloma is astounding and this is the first time that a personalized therapy has been identified to be effective for myeloma patients with a particular genetic feature.
Jonathan Kaufman, MD of Emory University's Winship Cancer Institute has been involved in early and later trials for venetoclax in multiple myeloma. Dr. Kaufman is Associate Professor, and serves as Associate Vice-Chair, and as Director of the Division of Hematology in the Department of Hematology and Med…
playlist_add
Oct 16, 2020
HealthTree Podcast for Multiple Myeloma: Syed Abbas Ali, MD, Johns Hopkins
Dr. Ali is the primary investigator on a clinical trial to use a vaccine to extend remissions following successful myeloma treatment. The GVAX study is open for patients who are MRD positive but don't yet have a measurable m-protein. Dr. Ali explains how the vaccine works and why patients may want to use it to lengthen theri remission times.
Thanks to our episode sponsor, Bristol Myers Squibb.
playlist_add
Sep 4, 2020
HealthTree Podcast: Krisstina Gowin, MD and Onyemaechi Okolo, MD, U of AZ
Since HealthTree for Multiple Myeloma started our advocacy work in myeloma, the most common question we get is “What supplements, diet or other alternative treatments will help my myeloma?” Whether it's yoga, supplements, massage therapy, Tai Chi, music therapy, IV vitamins or guidance therapy, Dr. Krisstina Gowin and Dr. Onytemaechi Okolo of the University of Arizona will discuss how integrative and alternative therapies can be used in myeloma care. They are also performing a study inside of HealthTree to learn what integrative therapies myeloma patients are using in addition to traditional myeloma therapy.
Thanks to our episode sponsor, Karyopharm
Whether you are using yoga, exercise, acupuncture, art therapy, vitamin D supplements, curcumin or other alternative treatments, Dr. Krisstina Gowin of the University of Arizona and the Mayo Clinic is performing research to better understand how widespread the use is for myeloma patients of these alternative therapies…
playlist_add
Jul 28, 2020
HealthTree Podcast for Myeloma : Keith Stewart, MB, CHB, Princess Margaret
Myeloma specialists and myeloma patients alike want to know which treatment will work best before they are taken. Dr. Keith Stewart and colleagues from the Mayo Clinic Scottsdale have developed a new test using a "direct-to-drug" screening that helps determine how certain myeloma cells (with specific biomarkers and pretreatment histories) will react to different myeloma therapies. The new test is flexible enough to accommodate new drugs as they become FDA approved and is a way to avoid using drugs that won't provide much impact. This flexibility is required with the rapidly changing environment in myeloma.
Personalized care in myeloma is especially tricky because of the differences in each myeloma patients' cells. A single patient can have an average of 5 different "types" of myeloma at diagnosis and those types can evolve over time. This is called heterogeneity. Add to that the large number of potential treatment combinations, and it becomes an art and a science to treat myelom…
playlist_add
Jun 5, 2020
HealthTree Podcast for Multiple Myeloma: Thomas Martin, MD UCSF
Isatuxiab (Sarclisa) by Sanofi Genzyme is a new CD38-targeting monoclonal antibody that is now FDA approved to be combined with pomalidomide and dexamethasone. In the same drug class as daratumumab, isatuximab is different in its mechanism and is now being used in additional clinical trials in combinations such as isatuximab/carfilzomib/dex and isatuximab/bortezomib/dex. The growing number of potential therapies is a big win for myeloma patients. Learn from myeloma specialist Thomas Martin, MD of the University of California at San Francisco about how the drug works, how it is being applied in the myeloma clinic and open clinical trials using it in new combinations. Dr. Martin will also cover the recent clinical trial results presented at the recent ASCO 2020 meeting.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
Jun 1, 2020
HealthTree Podcast for Multiple Myeloma: Paul Richardson, MD, Dana Farber
Myeloma progress continues to occur, in spite of the coronavirus and myeloma patients need to stay up-to-date on advancements in order to receive excellent myeloma care. The myeloma arsenal of treatments is growing, with several new treatments approved in the last few months and more to be approved in 2020. Dr. Paul Richardson of the Dana Farber Cancer Institute provides the myeloma patient community with a great synopsis of all relevant announcements shared at the virtual American Society of Clinical Oncology (ASCO) meeting held May 29-31, 2020. Learn what's coming shortly in immunotherapies, precision medicine, targeted therapies, combination therapies and much more in this important show.
Thanks to our episode sponsor, GlaxoSmithKlein
playlist_add
May 29, 2020
HealthTree Podcast for Myeloma: Stephen Russell, MD, PhD, Mayo Clinic and Vyriad
Antibody testing for COVID-19 is rapidly evolving on a daily basis. Dr. Stephen Russell is developing a new blood-based antibody test to identify neutralizing antibodies that can determine a person's immune defense against SARS-CoV-2.
The project is a collaboration between Dr. Russell's company Vyriad and the pharma company Regeneron, and wants to make the tests commercially available through major labs soon. Dr. Russell notes that there are many different antibodies, some of which can neutralize the virus. And that those antibodies are the important ones that can tell if a patient will be protected against reinfection or not. He started looking into ways he could respond to the virus in February and a clinical trial quickly opened to study the test. Learn more about antibody testing in general and this test in particular on this fascinating show.
Thanks to our episode sponsor, Genentech.
playlist_add
Apr 13, 2020
HealthTree Podcast for Multiple Myeloma: Ola C. Landgren, MSKCC
To date, a select number of myeloma patients have become COVID-19 positive. What have they experienced and how have they fared? Dr. Ola Landgren of Memorial Sloan Kettering Cancer Center is living in New York City, a major hot spot in the United States for COVID-19. He joins us on HealthTree Podcast for Multiple Myeloma to share his expderiences in treating COVID-19 positive patients and his suggestions for myeloma patients who have not been infected with COVID-19. Join us for this relevant and important program during this critical time for myeloma patients.
Thanks to our episode sponsor, Takeda Oncology.
playlist_add
Mar 20, 2020
Myeloma Crowd Radio: Joshua Richter, MD, Mount Sinai
The coronavirus (COVID-19) is causing concern and disruption for normally healthy global citizens, but there are additional issues for multiple myeloma patients who are frequent visitors to hospitals and are often immunocompromised. Learn from myeloma expert Joshua Richter, MD of Mount Sinai about current recommendations for multiple myeloma patients regarding treatments, doctor visits, blood draws, stem cell transplant and other infusions in light of this unique global situation. Learn more about what myeloma patients can do to protect themselves during this important time,
Thanks to our episode sponsor, Bristol Myers-Squibb
playlist_add
Feb 26, 2020
Myeloma Crowd Radio: Jennifer Saullo, MD, PharmD, Duke University
Infection is a leading cause of death for multiple myeloma patients and protection against infection is key, especially during stem cell transplant. At certain points during stem cell transplant, your immune system is at an all time low until your immune system “reboots” when stem cells are given back. Learn from transplant expert Jennifer Saullo, MD, PharmD of Duke University Medical Center as she shares ways to protect myeloma patients from infections before, during and after stem cell transplant.
Dr. Saullo is Assistant Professor of the Division of Infectious Diseases at Duke University. She serves on editorial boards of the Open Forum Infectious Diseases and reviews journals including Medical Mycology, BMJ Case Reports, and Clinical Infectious Diseases. She received the Meritorious Service Award at Duke, and several teaching and resident awards from Columbia University.
Dr. Saullo performs both basic and applied research on topics such as mass spectrometry, B cell immune…
playlist_add
Jan 30, 2020
Myeloma Crowd Radio: Robert Z. Orlowski, MD, PhD, MD Anderson Cancer Center
What innovation is coming in 2020 in myeloma research? Dr. Robert Orlowski of the the MD Anderson Cancer Center shares the insights learned from the recent American Society of Hematology meeting and highlights leading edge research expected in 2020. There is a stunning amount of development happening in myeloma - immunotherapies like CAR T, bi-specific antibodies, tri-specific antibodies and antibody drug conjugates, new findings in precursor conditions like MGUS and smoldering myeloma, new targeted therapies for relapsed and refractory myeloma and a host of different treatment combinations. Dr. Orlowski will give a broad and comprehensive review of what we can expect to see in 2020. Join us for this favorite annual show.
Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Onco…
playlist_add
Nov 6, 2019
Myeloma Crowd Radio: Tanya Wildes, MD, Washington University
Many myeloma patients are elderly, with the average age of diagnosis being 68. If individuals are fit and active, they can typically receive the "standard of care" drugs such as stem cell transplant or triplet drug combinations. But many individuals may be frail or have other health conditions that would required doctors to adjust treatment accordingly. Dr. Tanya Wildes, MD of the Washington University Siteman Cancer Institute shares how treatment can be modified for more frail patients and how therapy should be personalized for us all.
Thanks to our episode sponsor, Takeda Oncology.
playlist_add
Oct 23, 2019
Myeloma Crowd Radio: Clifford Reid, PhD, Travera
How much does a cancer cell weigh? And why does it matter? As cancer cells die, they change their weight in a matter of hours. A new device called the Suspended Microchannel Resonator (SMR) is a new technology that can measure a small change in the weight of a single cancer cell. The SMR machine can detect this change and tell whether a cancer cell has died of "natural causes" or if it was killed by a cancer drug. This allows rapid assessment of whether an individual patient is responding to a cancer treatment or not. This wraps together everything about a cancer patient (such as their myeloma genetics, environmental and other biological factors) and analyzes the response to treatment, making it truly personalized medicine. A company called Travera is now working to commercialize this technology developed in the Manalis Laboratory in the Koch Institute for Integrative Cancer Research at MIT. It was recently tested in multiple myeloma in a small study at Dana Farber. Learn more about…
playlist_add
Sep 30, 2019
Myeloma Crowd Radio: Natalie Callander, MD, University of Wisconsin
Cellectar Biosciences is working on testing a radiosensitive therapy in blood cancers including multiple myeloma. Their product, CLR 131, targets the myeloma tumors by delivering a cytotoxic radioisotope, iodine-131 directly to the tumor cells. Phase I study results showed an overall mean survival rate of 26.2 months for relapsed/refractory myeloma patients (who had received on average 5.8 prior lines of therapy). The drug was given as a one or two-dose treatment as a single agent, given during a 30-minute infusion. These results are promising when compared to recently FDA-approved myeloma treatments.
A Phase II study is now open using CLR 131 and dexamethasone for blood cancer patients including: multiple myeloma (MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) who have been previously treated with standard therap…
playlist_add
Sep 4, 2019
Myeloma Crowd Radio: Irene Ghobrial, MD, DFCI, PROMISE Study
Irene Ghobrial, MD of the Dana Farber Cancer Institute and Ivan Borrello, MD of Johns Hopkins are leading the largest study on precursor myeloma conditions that will include 50,000 patients and family members. The goal of the study is to detect myeloma early and see why and how patients who have MGUS and smoldering myeloma progress to active myeloma. The study is also seeking to understand the genetic, molecular and immune factors that lead to disease progression with the hope that this knowledge could stop disease progression and improve survival with effective strategies.
If you are African American or family member of a myeloma patient between the ages of 40-75, it's time to join this important study, which requires no travel. These two groups are involved in the study because they are more likely to develop into active myeloma. The Dream Team will study this group in an effort to define biological characteristics that will help to identify which patients will benefit from…
playlist_add
Aug 20, 2019
Myeloma Crowd Radio: William Matsui, MD, University of Texas Dell Medical School
Why is a myeloma specialist so important? What does it take to create a new myeloma research center from scratch? William Matsui, MD recently left Johns Hopkins to do just that. Dr. Matsui is the Deputy Director of the new University of Texas Dell Medical School's LIVESTRONG Cancer Institutes myeloma program. Learn what it takes to develop a new myeloma research center and lab and how it helps develop new strategies that could potentially extend lives. Dr. Matsui's unique focus on precursor stem cells, allo transplant approaches and immunotherapy in myeloma care will also be discussed.
William Matsui, MD is Deputy Director of the LIVESTRONG Cancer Institutes at Dell Medical School. He specializes in caring for patients with cancers that involve the blood and bone marrow as well as bone marrow transplantation. Matsui came to Austin from the Johns Hopkins University School of Medicine, where he was a professor of oncology and served as the director of the Multiple Myeloma Program an…
playlist_add
Jul 31, 2019
Myeloma Crowd Radio: Paul Richardson, MD, Dana Farber Cancer Institute
A new treatment called Selinexor was recently approved for highly relapsed multiple myeloma patients. Learn how experts like Dr. Paul Richardson of the Dana Farber Cancer Institute are using this new drug in their myeloma practice. Dr. Richardson will share how the drug works, when and how it should be used, potential side effects to watch out for and manage and why the new option is adding to patients' treatment choices.
Paul Richardson, MD is RJ Corman Professor of Medicine at Harvard Medical School and Attending Physician in the Division of Heamatologic Oncology in the Multiple Myeloma and Bone Marrow Transplant Service at the Dana Farber Cancer Institute. Dr. Richardson is the Clinical Program Leader and Director of Clinical Research for The Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute.
Thank you to our episode sponsor, GlaxoSmithKlein.
playlist_add
May 24, 2019
Myeloma Crowd Radio: Alexander Lesokhin, MD, Memorial Sloan Kettering CC
Immunotherapy is a major class of therapy that continues to expand in the myeloma clinic. Dr. Alexander Leshokin of Memorial Sloan Kettering Cancer Center explains the various types of immunotherapies: transplant, monoclonal antibodies, bi-specific antibodies, antibody drug conjugates, cellular therapies like CAR T, vaccines and where each type of treatment is at in the various stages of development.
Dr, Alexander Lesokhin is Assistant Attending Physician at Memorial Hospital for Cancer and Allied Diseases and Assistant Member of Memorial Sloan Kettering Cancer Center. He is an active member of ASCO and ASH and has oversight of fellows and residents in the transplant, lymphoma and myeloma units. Dr. Lesokhin performs significant immunotherapy research and is engaged in studies to perform work in the lab that will bridge to the clinic as to why cancer cells can evade the bone marrow derived tumor-infiltrating cells. He is also performing research on checkpoint inhibitors and why T…
playlist_add
May 20, 2019
Myeloma Crowd Radio: Rafael Fonseca, MD, Mayo Clinic Scottsdale
STEP therapy is an approach in managed medical care to minimize costs of prescription drugs. The program allows patients to begin therapy with the most cost-effective drugs and work their way up to more costly therapies only if necessary. It is also called "step protocol" or "fail first" and is a type of prior authorization requirement. Upward trends for prescription medications in the United States has led to an increased pressure on health care providers to keep medication costs down while maintaining drug availability. The cost controlling measures could impact cancer therapies for all patients, but it may be a particular challenge for myeloma patients who tend to used combination therapies in a serial fashion. Learn more about this and other issues about cost in myeloma care with Dr. Rafael Fonseca, Chair the Mayo Clinic Scottsdale program.
Dr. Rafael Fonseca is the Chair of the Department of Internal Medicine and Professor of Medicine at the Mayo Clinic in Scottsdale. He is als…
playlist_add
May 3, 2019
Myeloma Crowd Radio: David Siegel, MD, PhD, John Theurer Cancer Center
CAR T therapy is becoming a hot area of early clinical trials for multiple myeloma patients, but most are personally customized for each patient. A company called Cellectis has developed an off-the-shelf CAR T that every patient can use. Instead of being an "autologous" CAR T treatment (where you use your own cells), this is also called an "allogeneic" CAR T, or a "donor"CAR T.
Many of the current CAR T therapies are going after a target called b-cell maturation antigen (BCMA). This It is going after a different target called CS1/SLAMF7. Learn more about this new treatment (called UCARTCS1) from David Siegel, MD, PhD of Hackensack University / John Theurer Cancer Center and how it will be used in early myeloma clinical trials.
Thanks to our episode sponsor: Celgene Corporation
playlist_add
Apr 18, 2019
Myeloma Crowd Radio: Yogesh Jethava, MD, University of Iowa
A new clinical trial is open combining low dose melphalan, a drug commonly used at high doses for stem cell transplant, and high dose intravenous Vitamin C. Learn more about how these two treatments work synergistically and why they have been combined in a clinical trial at the University of Iowa. The University of Iowa has unique experience with IV Vitamin C and Dr. Yogesh Jethava joins Myeloma Crowd Radio to share this fascinating open study now enrolling patients.
Dr. Yogesh Jethava is Associate Professor and Director of the Multiple Myeloma program as well as Associate Director of the Blood and Marrow Program at the University of Iowa. Prior to this appointment, he was director of the Bone Marrow and Stem Cell Transplant Services Division of Hematology Oncology at the Winthrop P. Rockefeller Cancer Institute at University of Arkansas for Medical Sciences or UAMS where he established the first fully functional allo transplant unit. There, he was Director and Attending Physician…
playlist_add
Feb 6, 2019
Myeloma Crowd Radio: Ravi Vij, MD, Washington University
A new monoclonal antibody called Isatuximab is advancing through clinical trials and is getting closer to FDA approval. This antibody targets CD38. Learn more from Dr. Ravi Vij of Washington University as he discusses the findings from recent clinical trials, how this drug will be used in the clinc and how it is different from other monoclonal antibodies previously approved. Dr. Vij was the senior author on the first Isatuximab paper published in Blood and has been involved in several clinical trials to date.
Dr. Ravi Vij is Associate Professor of Medicine at the Washington School of Medicine in the Bone Marrow Transplant section. He received his medical degree in India and did follow-up training and residency at Rush-Presbyterian St. Luke’s Medical Center in Chicago and fellowships in Oncology and Bone Marrow Transplantation with Stem Cell Biology at Washington University.
He’s a member of ASCO, ASH, the St. Louis Society of Clinical Oncology, and the American Association for…
playlist_add
Jan 8, 2019
Myeloma Crowd Radio: Dr. Robert Z. Orlowski, MD Anderson Cancer Center 2019
Major progress is being made in the field of multiple myeloma including a vast array of immunotherapy options. Learn about key findings from the recent ASH conference in addition to what we can look forward to in the coming year. Listen to myeloma expert Robert Z. Orlowski, MD, PhD of the MD Anderson Cancer Center as he reviews the up-and-coming choices for the clinic and those new treatments in clinical trials.
Dr. Orlowski is Director of the Myeloma Section, Department of Lymphoma and Myeloma at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including th…
playlist_add
Dec 14, 2018
Myeloma Crowd Radio: Cesar Rodriguez, MD, Wake Forest University
Testing Your Individual Myeloma Tumor Against Available Myeloma Therapies
Each myeloma patient's tumor is unique and can change over time. Dr. Rodriguez is using a new 3D organoid tumor modeling platform which allows the testing of over 50 myeloma treatment combinations against your specific tumor (including your bone marrow microenvironment) to identify which treatments will work best for your type of myeloma. This personalized approach will help you find useful drug combinations that will have the most impact and avoid treatments that will be ineffective. Learn more in this fascinating show.
Thanks to our episode sponsor: Takeda Oncology
playlist_add
Dec 11, 2018
Myeloma Crowd Radio: Frank Zhan, PhD and Yogesh Jethava, MD, University of Iowa
Targeting CD24 to Eliminate Myeloma Stem Cells
Myeloma stem cells (or early progenitor cells before they become plasma cells) may not be killed with current myeloma therapies and could be the cause of relapse. Dr. Zhan has identified the presence of CD24 as a strong candidate as a cancer stem cell marker and believes that high CD24 levels lead to more aggressive myeloma and earlier death. His work will test patient samples for the presence of CD24 and assess outcomes while also identifying CD24 monoclonal antibodies that could impact this target. Learn more from Dr. Zhan and Dr. Yogesh Jethava of the University of Iowa in this Myeloma Crowd Research Initiative show. Donate to the MCRI here: give.crowdcare.org/mcri
Thanks to our episode sponsor, Celgene Corporation.
playlist_add
Nov 19, 2018
Myeloma Crowd: David Chung, MD, PhD, Memorial Sloan Kettering Cancer Center
Why do some multiple myeloma patients relapse early after stem cell transplant while others stay in remission for many years? The immune system may be a key factor.
David Chung, MD, PhD of Memorial Sloan Kettering Cancer Center was recently selected as a Myeloma Crowd Research Initiative (MCRI) award recipient.
The goal of the MCRI is to help optimize myeloma therapy for individual patients. Dr. Chung's research will review patients who have undergone stem cell transplant. He will study three different parts of the immune system after transplant - T cells, lymphocytes and myeloid derived suppressor cells (MDSCs) and will compare early vs. late relapse. He will then combine that immune system signature with the myeloma genetics of each patient to understand the impact they have together.
Learn why studying the immune system may be just as important as the study of myeloma genetics and what this research can mean for you personally.
The Myeloma Crowd created the MCRI because w…
playlist_add
Oct 29, 2018
Myeloma Crowd Radio: Dave Winfield and Don Baylor Jr. on your Most Valuable Plan
In the World Series and the world of baseball, a strategy for success means planning ahead - doing everything you can to come out a winner. In the world of multiple myeloma, that means being your best advocate and coming up with your Most Valuable Plan. Which doctor will you choose, what treatments will you receive and in what order? Having a game plan is essential to making sure you stay in the game. Join us as we talk with twelve-time MLB All-Sar and Hall-of-Famer Dave Winfield, whose close friend and former teammate Don Baylor passed away following a 14-year old battle with the disease. Together with Don's son, Don Baylor Jr., both are committed to helping raise awareness for this incurable blood cancer.
playlist_add
Oct 3, 2018
Myeloma Crowd Radio: Ashraf Badros, MD, University of Maryland
African Americans are twice as likely to be diagnosed with the rare blood cancer called multiple myeloma than white Americans and other ethnicities. Why is this and what can we do to ensure that this population obtains their very best care? Learn more about the genetics, younger diagnosis and other unique features for these patients and what we could do to increase life expectancy. Dr. Ashraf Badros of the University of Maryland joins us for this important and life-saving show.
Thanks to our episode sponsor, Celgene Corporation.
playlist_add
Sep 20, 2018
Myeloma Crowd: Irene Ghobrial, MD, Dana Farber Cancer Institute
Stand Up To Cancer has announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma, an incurable blood cancer of plasma cells, through early detection of precursor conditions before they turn into full-blown disease.
The team will be led by Irene Ghobrial, MD at Dana-Farber Cancer Institute (DFCI) in Boston and Ivan M. Borrello, MD, of Johns Hopkins University School of Medicine.
The hypothesis of this proposal is that early detection of MGUS/SMM in a high-risk population, along with a good understanding of the molecular and immune factors that lead to disease progression, will lead to effective strategies that intercept disease progression and improve survival.
The Dream Team proposes to conduct a screening study of individuals over the age of 45, who are at a high risk for having MGUS or SMM, such as African-Americans and individuals who have a first-degree relative that has been diagnosed with a plasma cel…
playlist_add
Sep 13, 2018
Myeloma Crowd Radio: Maria Chaudhry, MD, Ohio State University
At last year's ASH meeting, there was excitement around a new antibody drug conjugate targeting a protein called BCMA from Glaxo Smith Klein. Results from their Phase I study showed that patients who had relapsed immunomodulators (like Revlimid), proteasome inhibitors (like Velcade) and even monoclonal antibodies (like daratumumab), responded when taking this drug alone (60% response rate).
Learn more from Dr. Maria Chaudhry of Ohio State University about current studies using this new drug and when patients could consider it in the course of their treatment.
Thanks to our episode sponsor, Celgene.
playlist_add
Aug 3, 2018
Myeloma Crowd: Paul Richardson, MD, Dana Farber Cancer Institute
The myeloma landscape is rapidly changing with many new advancements. Paul Richardson, MD of the Dana Farber Cancer Institute joins Myeloma Crowd Radio to share recent updates from major summer meetings including the American Society of Clinical Oncology and European Hematology Association meeting and several others.
Thanks to our episode sponsor, Takeda Oncology.
playlist_add
Jul 30, 2018
Myeloma Crowd Radio: Brian McMahon of SparkCures (rescheduled)
How do multiple myeloma patients get into clinical trials? Especially those using popular new science like CAR T therapy? Brian McMahon, founder of SparkCures shares tips and tricks to get into these trials. Brian is the founder of SparkCures, a multiple myeloma clinical trial finder tool that simplifies the process. Brian shares his experience helping individual myeloma patients join these trials and will share the ins and outs of clinical trial participation. Join us and call in with questions on this practical show that can help you navigate your disease.
Thanks to our episode sponsor, Celgene Corporation
playlist_add
May 28, 2018
Myeloma Crowd Radio: Muhamed Baljevic, MD, University of Nebraska Medical Center
Many multiple myeloma patients can become resistant to an important class of myeloma drugs called proteasome inhibitors. Researchers found that expression of MUC20 could help predict how sensitive or resistant patients would be to proteasome inhibitors and found that MUC20 protein could be potentially impacted by an already FDA-approved drug offered by Amgen.
Learn more from Dr. Muhamad Baljevic of the University of Nebraska Medical Center about how this new drug is being used in a Phase I/II clinical trial to see if patients who have become resistant to carfilzomib can overcome that resistance by adding this new drug to the mix. These new c-MET inhibitors could have broader use in myeloma combinations.
Thanks to our episode sponsor, Celgene Corporation.
playlist_add
May 18, 2018
Myeloma Crowd Radio: HealthTree With Rafael Fonseca, MD, Mayo Clinic
A new tool for multiple myeloma patients is coming in June! Join us as we discuss the Myeloma Crowd's new initiative called HealthTree with Rafael Fonseca, MD of the Mayo Clinic in Scottsdale.
HealthTree will help myeloma patients understand their personally relevant treatment options, find clinical trials, track lab data and help accelerate research towards a cure.
Over 80% of myeloma patients are treated by general oncologists, yet data shows that patients who see myeloma specilists can live 38% longer. This is true because myeloma is a highly complex cancer to treat. HealthTree was designed to help you have better discussions with your doctor about options that may be available to you so you can receive optimal care for your specific situation. The tool also allows patients and researchers to view anonymous long-term data about the collective patient experience, providing new hypotheses about better patient care.
This summer, we will be canvasing the United States and h…
playlist_add
Apr 16, 2018
Myeloma Crowd Radio: Luciano Costa, MD, PhD, University of Alabama
Adequate treatment of multiple myeloma at diagnosis is a key issue for patients because their first remission is typically the longest and most durable. Dr. Luciano Costa of the University of Alabama joins Myeloma Crowd Radio to discuss a trial testing some of the best therapies for myeloma up-front: lenalidomide, dexamethasone, carfilzomib and daratumumab followed by a stem cell transplant. The same four drugs will be used after transplant as "consolidation" therapy.
The goal is to understand how much treatment could be needed to get patients into a complete remission status where no myeloma is detectable (also called minimal residual disease negative or MRD status). The four drug combination will be used before transplant. If, after the transplant, the patient still has detectable multiple myeloma, they will proceed to a series of consolidation blocks, up to three, consisting of four cycles of the KRdD at specified dosages and time frames. Patients who still show detectable disease…
playlist_add
Mar 12, 2018
Myeloma Crowd Radio: Veronika Bachanova, MD, PhD, University of Minnesota
Natural killer cells are the body's way of eliminating cancerous cells. When a myeloma patient's immune system is too weak, the natural killer cells can't effectively do their job to eliminate myeloma. A study is now being done to test donor natural killer cells in relapsed myeloma patients. The natural killer cells are collected and combined with IL-2 to help them grow and expand. Elotuzumab is used to help the NK cells migrate to the myeloma tumor and has anti-myeloma effect on its own. Learn more about this treatment that could help myeloma patients who are relapsed or refractory to standard myeloma therapies or help them bridge to other therapies like allogenic transplant or future CAR T studies.
Thanks to our episode sponsor, Celgene Corporation.
playlist_add
Feb 16, 2018
Myeloma Crowd Radio: William Matsui, MD, Johns Hopkins University
Allogeneic stem cell transplant was the first ever immunotherapy available for mulitple myeloma patients. Dr. Matsui shares how the Johns Hopkins allo transplant procedure has significantly improved safety concerns. His research is now focused on extending and deepening remissions with a new immunotherapy antibody given with transplant. Dr. Matsui will also share his latest research on precursor myeloma cells (called myeloma stem cells) and how they can be targeted before growing into full blown myeloma.
playlist_add
Feb 11, 2018
Myeloma Crowd Radio: Martin Kaiser, MD, The Institute of Cancer Research, UK
Dr. Martin Kaiser joins Myeloma Crowd Radio to share more about the latest advances in myeloma treatment in the United Kingdom and how the use of myeloma genomic data with thousands of patients in the UK is furthering new insights in myeloma care.
Thanks to our episode sponsor, SparkCures. SparkCures provides an easy way to find and join multiple myeloma clinical trials.
playlist_add
Jan 5, 2018
Myeloma Crowd Radio: Robert Orlowski, MD, PhD, MD Anderson Cancer Center
The year 2018 promises to be an exciting one in multiple myeloma research. Learn what about key findings from the recent ASH conference in addition to what we can look forward to in the coming year. With the explosion of immunotherapy and combination approaches now in the clinic and in clinical trials, the choices are greatly expanding for myeloma patients. Listen to myeloma expert Robert Z. Orlowski, MD, PhD of the MD Anderson Cancer Center as he reviews the up-and-coming choices for the clinic and those new treatments in clinical trials.
Dr. Orlowski is Director of the Myeloma Section, Department of Lymphoma and Myeloma at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Bo…
playlist_add
Oct 17, 2017
Myeloma Crowd Radio: Diahanna Valentine, Critical Care Financial Consulting
Multiple myeloma treatment can cause "financial toxicity" for patients who are trying to pay for care that will give them optimal outcomes. Diahanna Valentine joins the Myeloma Crowd to discuss financial resources that are available to myeloma patients in this informative. show.
Diahanna is Owner and Founder of Critical Care Financial Consulting, LLC which takes a holistic approach to managing your finances in the face of a critical or chronic illness. She is an 18+ year Financial Advisor, providing Holistic planning for individuals and businesses and has 9+ years as a project Manager in Healthcare Services, Construction and the Investment Industries. Diahanna has a BA in Political Science and is HIPPA Certified. She also received her training as an Oncology Financial Patient Advocate from George Washington University. Diahanna is Licensed as a Health and Life Agent and is also maintains her Series 7 Investment Brokers License as well as the 63, and 66. Until recently, Diahanna was…
playlist_add
Sep 27, 2017
Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber
Myeloma patients can't wait until blood-based "liquid biopsies" replace the dreaded bone marrow biopsy. Painful and intrusive, the bone marrow biopsy is today's "standard" of myeloma testing to determine levels of myeloma disease burden in patients. These biopsies need to be performed at diagnosis, relapse and repeated every so often to determine response to treatment. Researchers at the Dana Farber Cancer Institute and the Harvard School of Medicine are creating a blood-based test that could provide easier measurements of disease burden. This would lighten the load for myeloma patients while still giving the needed information to measure disease progression and response to therapy. Learn more in this compelling show.
playlist_add
Aug 25, 2017
Myeloma Crowd Radio: Michael O'Dwyer, MD, National University of Ireland
Sugar molecules could act as a smoke screen for multiple myeloma cells, essentially hiding them from the immune system. The surface sugars, called sialic acids, can mark the cancer cells as “self” cells, giving the immune system the signal to ignore them.
Dr. Michael O'Dwyer is Director of the Blood Cancer Network Ireland and Professor of Hematology at the National University of Ireland Galway. Dr. O'Dwyer has expertise in the glycosylation process as it relates to multiple myeloma. The glycosylation process (or the reaction when carbohydrates is attached to other molecules) is a process that produces DNA, RNA and proteins. This normal process is altered in multiple myeloma and could cause changes in cell signaling, adhesion and drug resistance. In this show we will explore how this affects multiple myeloma, if food intake is related to the presence of sugar molecules and how it is tested for in myeloma.
In 2015, Dr. O'Dwyer received a Clinician Scientist Award worth €1.7m…
playlist_add
Jul 19, 2017
Myeloma Crowd Radio: Sagar Lonial, MD, Winship Cancer Institute
The recent meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) occurred recently in May and June. There are a wealth of updates on up-and-coming therapies, use of combinations to improve outcomes, strategies to reduce side effects and much more from myeloma specialists across the world. Dr. Sagar Lonial will join us to share an overview of the major themes in myeloma advances from his leading-edge perspective.
Dr. Sagar Lonial is an internationally recognized as a leading authority in multiple myeloma treatment and research. A Board certified hematologist and medical oncologist, Dr. Lonial staffs and works both on the transplant service as well as in the B-cell malignancy clinic.
Dr. Lonial is involved in numerous professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation. He serves as Vice Chair of the Myeloma C…
playlist_add
May 24, 2017
Myeloma Crowd Radio: Drs. Anja Seckinger and Dirk Hose, University of Heidelberg
Many patients are familiar with the monoclonal antibodies daratumumab and elotuzumab. These target a specific protein on the surface of myeloma cells. A new approach is in progress to target both a protein on the surface of myeloma cells (BCMA) while also activating the immune system's T cells. This is called a bi-specific antibody, going after two targets at the same time. Join us to learn more about this fascinating approach from German researchers Anja Seckinger, MD and Dirk Hose, MD of the University of Heidelberg. This could provide an off-the-shelf immunotherapy for myeloma patients that gives myeloma a double punch.
Special thanks to our episode sponsor, Takeda Oncology.
playlist_add
Apr 26, 2017
Myeloma Crowd Radio: Elisabet Manasanch, MD, MD Anderson Cancer Center
Can the genetics of myeloma or other clinical factors predict who will progress from early conditions like MGUS and smoldering myeloma to active myeloma? Dr. Elisabet Manasanch of the MD Anderson Cancer Center is hosting a study in partnership with Signal Genetics/Quest to determine what is meaninfgul (or not) in determining who is most likely to progress and is thus most likely to receive treatment. Dr. Manasanch is also studying the new monoclonal antibody Isatuximab in a clinical trial for high-risk smoldering myeloma patients. The road to a cure may be earlier treatment in these precursor conditions while the disease is not as complex or aggressive. Learn more about this fascinating work to prevent myeloma from happening in the first place.
playlist_add
Mar 31, 2017
Myeloma Crowd Radio: Dr. Guido Tricot, MD, PhD, University of Iowa
Today's myeloma therapy can help patients gain remission, but the combinations can cause their own side effects because they target normal cells as well as cancer cells. Investigators at the University of Iowa including Dr. Guido Tricot and Dr. Frank Zhan have tested mega-doses of Vitamin C in combination with the standard chemo melphalan and found that the Vitamin C can kill myeloma cells while not affecting normal cells. Additionally, it boosts the power of melphalan, so that melphalan can be used in smaller doses with fewer side effects. Learn more about this exciting discovery in this show
Thanks to our episode sponsor, Takeda Oncology.
playlist_add
Mar 24, 2017
Myeloma Crowd Radio: Gareth Morgan, MD, FRCP, PhD, UAMS Myeloma Instititue
Dr. Gareth Morgan of the UAMS Myeloma Institute joins us to share more about the Myeloma Genome Project, a global effort to create a broad collection of high-quality genomic and clinical data from multiple myeloma patients to improve diagnosis, prognosis and treatment.
The project will compile a broad set of genetic data and resulting outcomes to develop a strategy to segment patients into groups for more specific types of treatment. It also hopes to develop specific tests for disease-associated genetic mutations.
The project is already integrating data sets from the UAMS Myeloma Institute, the National Cancer Research Institute's Myeloma XI trial, Intergroupe Francophone du Myeloma/Dana-Farber Cancer, and the Multiple Myeloma Research Foundation.
Hear more about what has been learned so far and the future of this important project.
Thanks to our episode sponsor, Takeda Oncology.
playlist_add
Feb 28, 2017
Myeloma Crowd Radio: Heather Landau, MD, Memorial Sloan Kettering Cancer Center
About 10-20% of multiple myeloma patients will develop a condition called amyloidosis during the course of their disease. Amyloidosis is a disease caused by protein buildup in organs such as the heart, kidneys, liver or intestines, leading to organ damage and complications associated with some multiple myeloma treatments. There are three major types of amyloidosis: primary, secondary, and hereditary. Each type of amyloidosis is classified by its underlying causes and the type of protein that accumulates in organs.
Primary amyloidosis is the most common form and occurs with multiple myeloma. The cause is unknown but the disease starts in the bone marrow. Fragments of abnormal antibodies (called light chains) stick to each other and accumulate in organs in the body.
Heather Landau, MD of the Memorial Sloan Kettering Cancer Center joins us for this episode of Myeloma Crowd Radio to discuss the latest therapies and clinical trials for amyloidosis patients.
Thanks to our episode sponso…
playlist_add
Feb 17, 2017
Myeloma Crowd Radio: Cristina Gasparetto, MD, Duke Cancer Institute
Allogeneic stem cell transplant is rarely used in multiple myeloma treatment, but for younger patients with high-risk myeloma, it could be a highly effective strategy with durable outcomes. Dr. Cristina Gasparetto from Duke University shares the rationale of this approach for a subset of myeloma patients and how improvements in reducing allo side effects (like graft vs. host disease) are making this type of transplant easier.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
Jan 12, 2017
Myeloma Crowd Radio: Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Ctr
For the last 50 years, myeloma studies have relied on myeloma progression measurements like complete response (CR) or progression free survival (PFS) to tell whether new treatmets are working (or not). Myeloma patients are now living longer because of new treatment advances, which is a huge blessing. But it is also a challenge for research. If the average patient is living 8-10 years, how can studies be performed and show results in the 2-3 year range so that the new drugs can be approved quickly?
Minimal residual disease testing can detect very low levels of disease and being MRD-negative is linked to patients living longer. Researchers would like to use MRD testing as a study measurement. Learn about the different types of MRD tests, how to have one done and why researchers want to use this test as an end-point in studies.
Dr. Ola Landgren of the Memorial Sloan Kettering Cancer Center is a pioneer in the MRD space and joins us for this important show.
Thanks to our episode sp…
playlist_add
Jan 5, 2017
Myeloma Crowd Radio: Dr. Robert Orlowski, MD, PhD, MD Anderson Cancer Center
The year 2017 promises to be an exciting one in multiple myeloma research. With so many new types of therapies in the clinic like immunotherapies, specific inhibitors and variations of combinations, the choices are expanding for myeloma patients. Listen to myeloma expert Dr. Robert Z. Orlowski of the MD Anderson Cancer Center as he reviews the up-and-coming choices for the clinic and those new treatments in clinical trials.
Special thanks to our episode sponsor, Takeda Oncology.
playlist_add
Dec 30, 2016
Myeloma Crowd Radio: Ask the Experts at the St. Louis Myeloma Crowd Round Table
It's a rare opportunity to have a panel of myeloma experts available to answer any myeloma patient question. Experts at our Myeloma Crowd Round Tables answered common patient questions at our meeting in St. Louis. Listen in to learn more about a wide variety of topics with experts that have over 80 years treating myeloma including: Guido Tricot, MD, PhD (University of Iowa), Morie Gertz, MD (Mayo Clinic), Keith Stockerl-Goldstein, MD (Washington University), and Ravi Vij, MD (Washington University).
Thanks to our Myeloma Crowd Radio episode sponsor Takeda Oncology
Thanks to our Myeloma Crowd Round Table sponsors: Takeda Oncology, Amgen and Signal Genetics
playlist_add
Dec 27, 2016
Myeloma Crowd Radio: Ivan Borrello, MD, Johns Hopkins School of Medicine
One of the two projects funded by the Myeloma Crowd Research Initiative is an immunotherapy called MILs (marrow infiltrating lymphocytes). For high risk myeloma patients, their T-cells are taken out, grown up a hundred fold in the presence of their tumor and then given back a post-transplant. Dr. Borrello gives us an update on his open clinical trlal for high risk patients and shares how is also using the MILs with allogeneic transplant and other future combinations (like with checkpoint inhibitors) and in earlier settings. This immunotherapy can be used in almost 100% of patients with fewer side effects than other types of immunotherapy approaches like CAR T cells.
You can support this project by donating here: The Myeloma Crowd Research Initiative (MCRI)
Special thanks to our Myeloma Crowd Radio episode sponsor, Takeda Oncology.
playlist_add
Nov 17, 2016
Myeloma Crowd Radio: Craig Cole, MD, University of Michigan
At the University of Michigan, Dr. Craig Cole is working on a collaboration with the MMRC to perform genomic sequencing on 500 hundred relapsed and refractory myeloma patients over a two year period. The goal is to share each patient's genomic profile to identify patient-specific treatment options. The study will be open at 11 myeloma academic centers to begin, with more to open in the future. The tissue samples collected at these centers are shipped to the University of Michigan Comprehensive Cancer Center, which then evaluates the alterations of 1700 genes. The study aims to find the specific mutations that are "actionable," or that have a drug that can be used. The study goal is to make myeloma treatment more precise for a disease that varies widely from patient to patient.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
Nov 11, 2016
Myeloma Crowd Radio: Dr. Sergio Giralt, MD, Memorial Sloan Kettering Cancer Ctr
According to multiple myeloma specialists, autologous stem cell transplant is not going away any time soon, even in the age of new therapies. Dr. Sergio Giralt is a myeloma specialist and a transplant specialist who shares what "transplant plus" could look like. Now that new treatments and drugs are in the clinic, what is being done to extend remission times for patients by adding something else to the transplant, either before, during or after? Dr. Giral weighs in with options that include immunotherapies like vaccines and other T cell treatments that could make transplant even more durable.
Special thanks to our episode sponsor, Takeda Oncology
playlist_add
Oct 28, 2016
Myeloma Crowd Radio: Nikoletta Lendvai, MD, PhD, Memorial Sloan Kettering
How do clinical trials work in multiple myeloma? Dr. Nikoletta Lendvai of the Memorial Sloan Kettering Cancer Center joins us to share information how how trials work, how patients can join and why they benefit by participating. She will also describe open clinical trials at her center including a new drug called Selinexor. Listen in and learn why clinical trials can bring us closer to a cure, faster.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
Oct 19, 2016
Myeloma Crowd Radio: Dr. Andrzej Jakubowiak, MD, PhD, University of Chicago
What can multiple myeloma patients try if they relapse current medications or treatments early? Or if the relapses continue and they become refractory to treatment? With newer drugs now available in the clinic, picking the right combinations at the right time is key for patients. Learn how to educate yourself about the current options and how to position yourself for your best care.
Dr. Andrzej Jakubowiak, MD, PhD of the University of Chicago is a myeloma expert who is deeply involved in the creation of clinical trials testing these newer combinations. He shares his expertise on the timing, staging and combinations that are being tested in clinical trials and what he is learning from these studies.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
Sep 28, 2016
Myeloma Crowd Radio: Dr. Torben Plesner, Vejle Hospital, Denmark
Now that daratumumab is being used in the clinic, myeloma specialists have more experience with its use. Learn why a new test is in the works to prevent patients from being taken off the drug when they are actually responding and which combinations are the most effective. Dr. Torben Plesner has been running daratumumab clinical trials since its inception and is a myeloma expert with extensive experience with the drug.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
Sep 16, 2016
Myeloma Crowd Radio: Dr. Robert Kyle, MD, Mayo Clinic
For over sixty years Dr. Robert Kyle, MD of the Mayo Clinic led the way in myeloma research and was the pioneer that defined and determined early precursor conditions MGUS and smoldering myeloma in the late 1970s and early 1980s. He joins us to share over 40 years of data from an extensive longitudinal study and his key findings on these precursor conditions of multiple myeloma. Dr. Kyle's groundbreaking work has changed how smoldering myeloma is diagnosed and treated. Learn what deep expertise can tell us about myeloma progression from these early stages and what it means for you.
Special thanks to our episode sponsor, Takeda Oncology
playlist_add
Aug 24, 2016
Myeloma Crowd Radio: MCRI Update with Michael Hudecek, MD
One year ago, we began raising funds for the Myeloma Crowd Research Iniatiive. With the help of an expert Scientific Advisory Board and a knowledgeable Patient Advisory Board, we selected two projects to fund: 1) a CAR T Cell research project targeting CS1 and BCMA from Drs. Hermann Einsele and Michael Hudecek from the University of Würzburg in Germany and 2) a T cell immunotherapy using marrow infiltrating lymphocytes (MILs) with transplant from Dr. Ivan Borrello of Johns Hopkins.
We've now provided an initial $100,000 to each research project. In this episode, Dr. Michael Hudecek gives us an update of his CAR T cell research from the grant award that the Myeloma Crowd Research Initiative has provided. Learn more about what we've done with YOUR support to help advance a cure in this important episode.
playlist_add
Aug 3, 2016
Myeloma Crowd Radio: Dr. Philip McCarthy, Roswell Park Cancer Institute
Stem cell transplants will continue to be a staple of multiple myeloma therapy because they are highly effective. But can we add something before or after transplant to make them even more powerful? With new maintenance therapies showing greater overall survival and with new drugs and immunotherapies in the mix, what can we add on the front or back end to make transplant even better? Hear from Dr. Philip McCarthy from the Roswell Park Cancer Institute, a stem cell transplant expert, about the use of maintenance treatments and up-front options that can give patients more durable outcomes.
playlist_add
Jul 15, 2016
Myeloma Crowd Radio: Using Nanotechnology in Multiple Myeloma
Nanotecnology is the study of very small things - won to the atom and molecule level. Researchers at Washingon University have been given a prestigious grant by the NIH to study nanotechnology in cancer and more specifcially, in multiple myeloma. Nanotechnology can deliver a higher concentration (by a hundred fold) of drug in a more targeted way. It can also usie imaging testing (like PET/CT) and MRI to find and selectively target cancerous cells. It can also help kick hiding myeloma cells out into the blood which can then be killed by myeloma drugs. This is a groundbreaking use of new technolgoy in cancer with a team of top experts.
playlist_add
Jun 10, 2016
Myeloma Crowd Radio: Dr. Don Benson, Ohio State University
You may have heard about checkpoint inhibitors - drugs that help take the breaks off the immune system to fight multiple myeloma. Learn more about how this new class of drugs is being used with all types of myeloma treatment and when they are best used from Dr. Don Benson, MD, PhD, an immunotherapy expert who has been actively researching this type of therapy for many years.
playlist_add
May 24, 2016
Myeloma Crowd Radio: ICER President Steven D. Pearson, MD, MSc
The Institute for Clinical and Economic Review’s (ICER) Midwest Comparative Effective Public Advisory Council (CEPAC) will hold is inaugural meeting on May 26, 2016 in St. Louis “to discuss the comparative clinical effectiveness and value of therapies of multiple myeloma.” The goal is to create recommendations that health insurers (or payers) will use to determine reimbursement levels for drugs used in myeloma treatment. Since the public announcement of ICER’s plan in February 2016, the draft reports have been strongly criticized by myeloma specialists, pharmaceutical companies, and more recently, patient advocates. Steven Pearson will discuss ICER’s perspective, addressing critics of ICER’s methodology, process, definitions of value, and, as of now, the lack of inclusion of patient views.
playlist_add
May 13, 2016
Myeloma Crowd Radio: Dr. Jacob Laubach, MD, MPP, Dana Farber Cancer Institute
While immunotherapy approaches expand, proteasome inhibitors remain a staple therapy of multiple myeloma. Learn why they work, how they differ, how the new oral version (Ninlaro) is bringing greater convenience to the clinic, why they continue to be developed and how they are being used in quad combinations with immunotherapies to fight myeloma. Dr. Jacob Laubach shares how they differ, who they work best for (and don't), when they should be used as maintenance therapy and how a new gene may give us clues into who will respond and who will not.
Thanks to our episode sponsor, Takeda Oncology.
playlist_add
May 6, 2016
Myeloma Crowd Radio: Dr. William Matsui, MD, Johns Hopkins Kimmel Cancer Center
Myeloma stem cells are believed to cause the growth of multiple myeloma. Many myeloma treatments kill the myeloma plasma cells, but according to William Matsui, MD of the Johns Hopkins Kimmel Cancer Center, these treatments may not affect the myeloma stem cells. Dr. Matsui recently presented results from a study he did with colleagues at Johns Hopkins testing a new monoclonal antibody with lenalidomide and dex. Just with len/dex, he saw myeloma stem cells increase by 2.5 times, but when the new monoclonal antibody was added, it decreased the myeloma stem cells by half. Learn more about this up and coming new target in clinical trials that can kill myeloma cells at their source.
playlist_add
Apr 26, 2016
Myeloma Crowd Radio: Melanie House, DPT, NCS, University of Iowa
Melanie House, DPT, NCS of the University of Iowa recently presented at Pat's Myeloma Survival School on physical issues that myeloma patients face before, during and after their treatment. As part of the Muscles for Myeloma series, she will give practical, real-world advice to make life more manageable for patients:
How to rebuild strength during and after treatment and how dex and bedrest waste musclesHow to prevent falls and improve balanceHow to manage peripheral neuropathyHow to increase enduranceHow to overcome that "so tired" feeling of fatigue post-treatmentWhat to do about shortness of breathHow to decrease back pain, muscles spasms and nerve pain
Thanks to our episode sponsor, Takeda Oncology
Thanks also to our Muscles for Myeloma sponsors: Sanofi Genzyme, Takeda Oncology and Celgene Corporation
playlist_add
Apr 15, 2016
Myeloma Crowd Radio: Dr. David Siegel, MD, PhD, John Theurer Cancer Center
The multiple myeloma aresenal is growing, giving myeloma experts more tools to combat the complex blood cancer, multiple myeloma. Learn how investigators like Dr. David Siegel, MD, PhD of the John Theurer Cancer Center are vetting treatment combinations using clinical trials to identify optimal treatment paths, especially for patients who are facing relapses or who have become refractory to existing medications.
Thanks to our episode sponsor, Takeda Oncology.
playlist_add
Mar 29, 2016
Myeloma Crowd Radio: Dr. Irene Ghobrial, MD, Dana Farber Cancer Institute
Can we prevent smoldering myeloma or MGUS from progressing to active myeloma? Dr. Irene Ghobrial, MD wonders why we are waiting until progression to treat when we have newer non-toxic therapies to use. Dr. Ghobrial shares her Prevention of Progression Clinic's efforts to keep myeloma at bay. In this show, she shares her open study (observational) that includes all MGUS and smoldering myeloma patients. It's easy to join - just mail her blood and marrow samples when you have your regular testing done and they will keep track of how progression happens and why.
playlist_add
Mar 11, 2016
Myeloma Crowd Radio: Dr. David Avigan, MD, Beth Israel Deaconess Medical Center
Immunotherapy combinations are just beginning. At the ASH 2015 conference Dr. David Avigan, MD of the Beth Israel Deaconess Medical Center shared his work to use a vaccine with an additional immunotherapy (a PD-1 blocker) and autologous transplant to make the transplant more durable and eliminate minimal residual disease. Learn more about this dendritic cell vaccine, how it works and why the road to immunotherapy will leverage the best available treatments for the best ultimate outcomes.
Thanks to our episode sponsor, Takeda Oncology.
playlist_add
Feb 25, 2016
Myeloma Crowd Radio: Dr. Muzaffar Qazilbash, MD, MD Anderson Cancer Center
Some treatments for multiple myeloma have been used for over two decades. With all of excitement around new treatments like immunotherapies, how do these two different worlds converge or collide? Learn from Dr. Muzaffar Qazilbash, MD of the MD Anderson Cancer Center about the utility of stem cell transplant in the age of immunotherapy and how these may be used alone or together for optimal outcomes.
Special thanks to our episode sponsor, Takeda Oncology
playlist_add
Feb 5, 2016
Myeloma Crowd Radio: Dr. James Berenson, MD, IMBCR
Multiple myeloma is typically tracked by measuring the M-protein, also called the "M-spike." But in some patients, the M-protein gets lost, making it difficult if not impossible to detect myeloma levels without a bone marrow biopsy. Dr. James R. Berenson, MD of the Institute for Myeloma & Bone Cancer Research has been working on a new test (assay) and has found direct correllations between levels of BCMA and the M-spike. He also has identified new clues that BCMA levels can provide related to outcomes within specific patient populations. Learn more in this show about a new and potentially easier way to detect myeloma, which would be incredibly valuable for the non-secretor.
Special thanks to our episode sponsor, Takeda Oncology.
playlist_add
Jan 22, 2016
Myeloma Crowd Radio: Dr. Kenneth Anderson, MD, PhD, Dana-Farber Cancer Institute
The advances found for multiple myeloma over the past two decades have been extroardinary. Much has been learned, and much has been accomplished with new treatment developments and arguably more discoveries than other cancers in the same time period. The past is impressive for this complex cancer, but there is more work to do. Dr. Ken Anderson helped lead the way for the discovery of new developments over a prestigious career of 40 years. He shares with us a brief look back and what he sees for the road ahead towards a cure.
Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at John’s Hopkins Hospital, and then c…
playlist_add
Jan 14, 2016
Myeloma Crowd Radio: Dr. Paul Shami, MD, Huntsman Cancer Institute
JSK is the first in its class with a new and unique method of killing multiple myeloma. It has a broad-spectrum anti-cancer activity, especially for myeloma and AML (acute myeloid leukemia) but is not toxic for normal cells. The JSK product is running through the standard approval process and is now in an advanced stage of pre-clinical development. Orphan drug designation has been obtained for myeloma and toxicology studies are now in the planning stages. JSK is active against drug-resistant myeloma cells and could be use with bortezomib to treat multiple myeloma. Dr. Paul Shami, MD of the Huntsman Cancer Institute joins us to describe the develoment and use of this new treatment now in development.
Thanks to our episode sponsor, Takeda Oncology.
playlist_add
Dec 18, 2015
Myeloma Crowd Radio: Dr. Robert Z. Orlowski, MD, PhD, MD Anderson Cancer Center
What happened at this year's American Society of Hematology (ASH) meeting in Orlando Florida? With three new drugs approved just before the start of the conference, there is so much to understand and absorb. Listen to Dr. Orlowski, MD, PhD of the MD Anderson Cancer Center give a simple explanation of the improvements in myeloma and some of his top takeaways in myeloma research.
Special thanks to our episode sponsor, Amgen.
playlist_add
Nov 20, 2015
Myeloma Crowd Radio: Dr. Ola Landgren, MD, PhD, Memorial Sloan Kettering
New developments for multiple myeloma are happening at an ever increasing pace. Dr. Ola Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center and heavily involved in the direction of myeloma research, both nationally and internationally. In this show he will give a wrap up of the recent Rome International Myeloma Working Group meeting as well as an ASH preview (for the upcoming December conference). He will also share up and coming clinical trials at Memorial Sloan Kettering Cancer Center to incorporate these new treatments into clinical practice. Learn what new drugs will be available and how they can be used in the myeloma clinic.
playlist_add
Nov 9, 2015
Myeloma Crowd Radio: Dr. Tomer Mark, MD, MSc, Weill Cornell Medical Center
Treatment for multiple myeloma is all about the combinations. Recently we've been hearing about the "BIRD" combinations. What are they and how effective are they? Learn from Dr. Tomer Mark, MD, MSc from Weill Cornell Medical Center about this new combination and what it means for myeloma patients.
playlist_add
Oct 16, 2015
Myeloma Crowd Radio: Dr. Djordje Atanackovic, MD, Huntsman Cancer Institute
With the explosion in immunotherapies for multiple myeloma, we have heard there are "windows" of best and most effective use. What are those windows and when is the best time to use these new approaches? The field is ever growing and Dr. Djordje Atanackovic will share how and when to use these new tools for a myeloma patient's best care.
Thanks to our episode sponsor, Takeda Oncology
playlist_add
Oct 8, 2015
Myeloma Crowd Radio: Dr. Adam Cohen, MD, Perelman Center for Advanced Medicine
The University of Pennsylvania had tremendous results with a recent clinical trial using a CAR T cell treatment targeting CD19 for a myeloma patient. The results were so impressive that some wonder if they have been able to eliminate the myeloma stem cell clone for one patient who had relapsed 9 therapies and had a high-risk genetic feature. Learn more about this success and where UPENN is going next using CAR therapy with Dr. Adam Cohen, MD, Director of Myeloma Immunotherapy at the Perelman Center for Advanced Medicine at UPENN.
Thanks to our episode sponsor, Amgen.
playlist_add
Sep 25, 2015
Myeloma Crowd Radio: Dr. Daniel Fowler, MD, NIH
Immunotherapies are making their way into the clinic and as they do, more exciting options will be available for patients. Researchers are now studying the best possible way to leverage the standard and effective multiple myeloma treatments with ways to empower the immune system to fight myeloma. Learn what Dr. Daniel Fowler, MD of the NIH is doing to use a Th1 and Th2 immune therapy treatment in combination with stem cell transplant in an early clinical trial.
Special thanks to our Myeloma Crowd Radio episode sponsor, Amgen.
playlist_add
Sep 18, 2015
Myeloma Crowd Radio: Dr. Don Benson, MD, PhD, Ohio State University
Dr. Don Benson, MD, PhD of The James Cancer Center at Ohio State University is a multiple myeloma specialist with deep expertise in immunotherapy. He shares the growing and exciting world of immunotherapies in multiple myeloma - how they work and how they are opening up an exciting new set of opportunities for myeloma patients.
playlist_add
Aug 17, 2015
Myeloma Crowd Radio: Dr. Mike Thompson, MD, PhD, Aurora Health Care
Social media tools can be used by doctors and patients to speed the time to cure, especially for rare diseases like multiple myeloma. Learn from myeloma specialist and oncologist Dr. Mike Thompson, MD, PhD from the Aurora Health Care how he is driving social media adoption in oncology to increase the speed for the discovery of a cure and what that means in the every day lives of myeloma patients.
Special Thanks to today's episode sponsor, Takeda Oncology.
playlist_add
Jul 29, 2015
Myeloma Crowd Radio: Dr. Jens Hillengass, MD, University of Heidelberg
Could an MRI predict how a multiple myeloma patient's disease will progress and respond to treatment? Learn what Dr. Jens Hillengass, MD of the University of Heidelberg is doing to use the latest in imaging techniques to learn more about an individual patient's myeloma and what it means for their outcomes and care.
playlist_add
Jul 21, 2015
Myeloma Crowd Radio: Dr. Alfred Garfall, MD, University of Pennsylvania
The University of Pennsylvania has led the charge in the US for CAR T cells for blood cancers with impressive results in leukemia. Dr. Alfred Garfall, MD was recently covered in Targeted Oncology for his research using CD19 in multiple myeloma. Learn more about the lessons learned in leukemia and how the exciting field is expanding and maturing in multiple myeloma.
playlist_add
Jun 12, 2015
Myeloma Crowd Radio: Dr. Brian Van Ness, PhD, University of Minnesota, PhD
Could multiple myeloma genetics give us clues into who will respond to standard treatments and who will not? Dr. Brian Van Ness, PhD of the University of Minnestota shares his study to do just that. In a collaboration between the Unversity of Minnesota and the Mayo Clinic, Dr. Van Ness will describe his study to determine who will respond to treatment (or not) even before the treatment is given. Learn more about how standard therapies can be effectively used in this important show.
playlist_add
May 29, 2015
Myeloma Crowd Radio/MCRI: Dr. Frits van Rhee, UAMS and Dr. Stephen Russell, Mayo
The measles virus used successfully for a patient with relapsed myeloma is now a well known and exciting story shared on maintstream media. Dr. Frits van Rhee MD PhD MRCP, FRCPath and Dr. Stephen Russell, MD PhD FRCP, FRCPath take the success one step further with a Phase II trial of the measles virus with further engineering in patients with relapsed/refractory, high-risk multiple myeloma. Their work will help determine which patients will respond to the treatment and which ones will not and will also determine how to make the therapy more effective.
playlist_add
May 27, 2015
Myeloma Crowd Radio/MCRI: Dr. Hermann Einsele, MD and Dr. Michael Hudecek, MD
CAR T cell therapy is a new and exciting potential treatment approach in blood cancers. It is a highly personalized treatment because the patient's own T-cells are redirected to erradicate cancerous cells after a single infusion, allowing patients to avoid the chronic side effects of long-term, toxic chemoradiotherapy. Learn more about Dr. Hermann Einsele, MD and Dr. Michael Huedecek, MD's work at the University of Würzburg, Germany to use a CAR T cell therapy targeting the CS1 protein commonly found on myeloma cells.
playlist_add
May 18, 2015
Myeloma Crowd Radio/MCRI: Drs. Gareth Morgan, Niels Weinhold and Christoph Heuck
UAMS has led the way in studying the biology of myeloma cells to find new therapies. We now know that multiple myeloma patients can have a variety of types of myeloma cells at the time they are diagnosed - some with more aggressive features than others. Researchers have found that patients with several different types of myeloma cells at diagnosis seem to have early relapse and shorter survival while patients with one dominant type of myeloma cell tend to do better. Learn what Dr. Gareth Morgan, MD, FRCP, FRCPath, PhD, Dr. Niels Weinhold, PhD and Dr. Christoph Hueck are doing to find out which clones are the most aggressive and which therapies increase the mutation rate, leading to a more resistant myeloma clone.
playlist_add
May 13, 2015
Myeloma Crowd Radio/MCRI: Dr. Carmen Baldino, PhD and Dr. Kelvin Lee, MD
Patients who have high-risk genetic features like the 14;16 translocation need new treatment options. Dr. Carmen Baldino of Jasco Pharmaceuticals and Dr. Kelvin Lee of the Roswell Park Cancer Institute are working on a potentially curative solution for patients with this high-risk translocation using a PIM2 Kinase inhibitor called JP-11646. Learn more about this proposal for the Myeloma Crowd Research Initiative to address the unmet needs for high-risk patients.
playlist_add
May 6, 2015
Myeloma Crowd Radio/MCRI: Dr. Frank Zhan, MD, PhD, U of Iowa
Myeloma is not a single disease. Two types of high-risk myeloma have swapped chromosomes (14;16) and (14;20) have notoriously short survival times with conventional treatments and are found to be resistant to bortezomib, one of the standard myeloma therapies. Dr. Frank Zhan, MD, PhD of the University of Iowa searched a genetic database to identify 100 genes uniquely deregulated for these two types of myeloma. Based on database matching to find compounds that induce or reverse desired gene changes, he found 5 targets to affect the c-MAF and MAFB genes that are disregulated by these translocations. They found that only Alsterpaullon (ALP) significantly inhibits MM cell growth with “spike” expression of either c-MAF or MAFB. ALP is a cyclindependent kinase (CDK) inhibitor and blocks cell-cycle progression. However, the reasons for its antiproliferative effects is unknown. The research will test whether ALP is able to disable c-MAF/MAFB signaling events, thus rendering MM resp…
playlist_add
Apr 30, 2015
Myeloma Crowd Radio/MCRI: Dr. Ivan Borrello, MD, Johns Hopkins, Immunotherapy
Dr. Ivan Borrello, MD of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, joins us as part of the top 10 projects selected by the Myeloma Crowd Research Initiative. He shares his pioneering work using patients' own immune cells to fight their cancer. His group leads the research for this type of immunotherapy, called adaptive T-cell therapy with MILS (marrow infiltrating lymphocytes). This vaccine is a version for multiple myeloma of those already successful to treat pancreas, prostate and breast cancers. Learn more about this important work in his upcoming study in multiple myeloma.
playlist_add
Apr 20, 2015
Myeloma Crowd/MCRI: Dr. Bruno Paiva, PhD, Universidad de Navarra, Flow Cytometry
Join us for our fourth episode of the new Myeloma Crowd Research Initiative of the proposals under consideration for the MCRI patient-led funding initiative. Dr. Bruno Paiva, PhD, is a multiple myeloma researcher from the University of Navarra Spain specializing in minimal residual disease (MRD) detection using flow cytometry. What does the newer MRD testing mean for high-risk patients? Dr. Paiva will describe his new study to find more clues and therefore better treatments for high-risk patients.
playlist_add
Apr 16, 2015
Myeloma Crowd Radio/MCRI: Dr. Robert Orlowski, MD, PhD, Del 17p
The third in our Myeloma Crowd Radio series for the new Myeloma Crowd Research Initiative (MCRI), we talk with Dr. Robert Orlowski, MD, PhD at MD Anderson Cancer Center about work being done specifically for the highest risk multiple myeloma patients with del17p.
This is a genetic feature with historically poor outcomes. Learn more about the hypothesis that the biology of del17p could be influenced to introducing genes normally repressed by p53 that would create molecular vulnerabilities and result in new targets to improve outcomes.
Special thanks to our Myeloma Crowd Radio episode sponsor, Takeda Oncology.
playlist_add
Apr 7, 2015
Myeloma Crowd Radio/MCRI: Dr. Guenther Koehne, MD, PhD, MSKCC
Join us for our second interview on Myeloma Crowd Radio highlighting the new Myeloma Crowd Research Initiative on high-risk myeloma. As part of this series, Dr. Guenther Koehne, MD, PhD of the Memorial Sloan Kettering Cancer Center will share his use of a T cell vaccine with an allogeneic transplant to provide outstanding results, even in plasma leukemia patients. His research pulls out T cells, marks them with a tag to target the WT1 protein, and are given back. He will describe how this works, the impact he has seen so far, the stage of his clinical trial and the work left to do to make this an available therapy for high-risk myeloma patients.
Dr. Guenther Kohene, MD, PhD is Medical Director of the Cell Therapy Laboratory in the Bone Marrow Transplantation Laboratory at Sloan Kettering. He is also Assistant Member and Assistant Attending Physician in the Allogeneic Bone Marrow Transplantation Service. He is Assistant Professor of the Joan and Sanford Weill Medical College of Co…
playlist_add
Mar 30, 2015
Myeloma Crowd Radio/MCRI: Dr. Craig Hofmeister, MD, OSU, CAR T cells
Join us for this first interview on Myeloma Crowd Radio highlighting new Myeloma Crowd Research Initiative on high-risk myeloma. For the first time, patients and doctors are joining together to find and fund research for patient group that is desperate for new options. The MCRI initiative reached out the the worldwide community and asked them to submit their research proposals for high-risk patients. We received 36 high quality proposals from all over the world. The MCRI Scientific Advisory Board then scored the proposals, selecting 10 for further review. These ten will be included in the Myeloma Crowd Radio/MCRI series on high-risk.
As part of this series, Dr. Craig Hofmeister, MD from Ohio State University will share his research being done to use engineered CAR T cells to specifically target the high-risk types of multiple myeloma.
Thanks to our episode sponsor, Takeda Oncology.
playlist_add
Feb 19, 2015
Myeloma Crowd Radio: Dr. Ajay Nooka, MD, MPH, FACP, Emory Winship CI
Can multiple myeloma be cured by shutting it down before it turns from smoldering to active myeloma? Dr. Ajay Nooka of the Emory Winship Cancer Institute joins us to talk about new, early-stage clinical trials being explored for smoldering myeloma patients including a new OncoPep vaccine to prevent progression.
playlist_add
Jan 29, 2015
Myeloma Crowd Radio: Dr. Ravi Vij, MD, Washington University
Are there new treatment options for the relapsed/refractory myeloma patient? Dr. Ravi Vij, MD of Washington University School of Medicine describes some newer approaches and therapies now in clinical trials.
playlist_add
Jan 9, 2015
Myeloma Crowd Radio: Dr. Robert Z. Orlowski, MD, PhD MD Anderson Cancer Center
Join us for the first show of 2015 with a review of the ASH conference's most important topics with Dr. Robert Orlowski, MD, PhD, University of Texas MD Anderson Cancer Center. The mPatient Myeloma Radio show change its name to Myeloma Crowd Radio beginning January of 2015. Follow us on Twitter @myelomacrowd or on Facebook at www.facebook.com/myelomacrowd.
playlist_add
Nov 20, 2014
mPatient Myeloma Radio: Dr. Vincent Rajkumar, MD, Mayo Clinic
The guidelines for myeloma treatment are changing to allow earlier treatment, even without some of the typical symptoms or disease damage. The goal is to treat earlier and prevent severe damage that myeloma causes. Learn more about these new guidelines from Dr. Vincent Rajkumar, MD of the Mayo Clinic on this very important show.
playlist_add
Nov 14, 2014
mPatient Myeloma Radio: Dr. Eric Bartee, MD, PhD, MUSC
When patients harvest stem cells in preparation for autologous transplant, can they be "cleaned up" or can all residual myeloma cells be completely removed before they are given back during transplant? Learn how Dr. Eric Bartee, MD, PhD of the Medical University of South Carolina is using a virus to do just that.
playlist_add
Oct 30, 2014
mPatient Myeloma Radio: Dr. Irene Ghobrial MD, PhD, Dana Farber Cancer Institute
Dr. Irene Ghobrial, MD, PhD of the Dana Farber Cancer Institute joins us to explain her recent discovery of a compound that can prevent myeloma from spreading into the bone, protecting patients from one of the most damaging effects of the blood cancer. Join us to learn more about this very exciting discovery.
playlist_add
Oct 3, 2014
mPatient Myeloma Radio: Dr. Jesus San Miguel, MD, PhD, University of Navarra
Join us as we talk with renown myeloma expert Dr. Jesus San Miguel of the University Hospital of Salamanca about high risk myeloma, recent findings of the International Myeloma Working Group and his work on minimal residual disease.
playlist_add
Sep 26, 2014
mPatient Myeloma Radio: Dr. Larry Kwak, MD, PhD, MD Anderson Cancer Center
Learn from Dr. Larry Kwak, MD, PhD about the latest in immunotherapy; specifically for vaccine use in myeloma. Dr. Kwak was noted on the 2010 Time list of Most Influential People for his vaccine work in lymphoma. As Professor and Chair of the Department of Lymphoma and Myeloma at the University of Texas M.D. Anderson Cancer center, he has 20+ years of experience in cancer vaccines and will share how his success in lymphoma is being advanced in myeloma.
playlist_add
Sep 19, 2014
HealthTree Podcast for Multiple Myeloma: Dr. Sarah Holstein, MD, PhD, RPCI
Join us as we talk with Dr. Sarah Holstein, MD, PhD of the Roswell Park Cancer Institute about her work to outsmart myeloma resistance and her work to target the bone marrow microenvironment via a variety of pathways.
playlist_add
Aug 29, 2014
HealthTree Podcast for Multiple Myeloma: Dr. Jay Bradner, MD, Dana Farber
Join us as we talk with Dr. Jay Bradner, MD of the Bradner Lab, Dana Farber Cancer Institute and Harvard Medical School. Dr. Bradner focuses his research on the use of chemical biology to target gene regulatory pathways. Specifically, Dr. Bradner is working to develop a MYC inhibitor for myeloma. MYC is the most common translocation to be found in multiple myeloma and increases in prevalance as the disease progresses, so finding a target for this translocations is critical.
playlist_add
Aug 25, 2014
HealthTree Podcast for Myeloma: Dr. Antonio Palumbo, MD U of Torino, Italy
Do all multiple myeloma patients need continuous maintenance therapy? Join us as we talk with Dr. Antonio Palumbo, MD on HealthTree Podcast for Multiple Myeloma about the recent data to suggest that this may be the case.
playlist_add
Jul 18, 2014
The New Hevylite® Myeloma Test with Dr. Stephen Harding, The Binding Site
Join us as we learn more about the new Hevylite® test for myeloma patients - when it should be used and why it is important with Dr. Stephen Harding of The Binding Site.
playlist_add
Jun 27, 2014
HealthTree Podcast for Myeloma: Dr. Saad Usmani, MD, Levine Cancer Institute
Join us as we talk with Dr. Saad Usmani, MD about his new position as Director of Clinical Research for Hematologic Malignancies and Director of Plasma Cell Disorders at the Levine Cancer Institute and his clinical trials for high-risk myeloma patients. Dr. Usmani was formerly at UAMS.
playlist_add
Jun 6, 2014
HealthTree Podcast for Myeloma: Dr. Brendan Weiss, Abramson Cancer Center, UPENN
Hear from Dr. Brendan Weiss, MD from the Abramson Cancer Center at the University of Pennsylvania about the indicators and factors that can MGUS progression to myeloma and a host of immunotherapy approaches that are up-and-coming both in the lab and clinic. He will also share his work on the bone marrow environment, how obesity impacts transplant, and how MGUS in racial groups.
playlist_add
May 30, 2014
HealthTree Podcast for Myeloma: Dr. Stephen Russell, MD, PhD, Mayo Clinic
Join us as we talk in detail about the recent announcement by the Mayo Clinic on Dr. Stephen Russell, MD, PhD's success in using the measles vaccine to halt myeloma growth. This major announcement was made earlier this week and patients want to know more. Dr. Russell will describe the long road to use vaccines to treat cancer, how that work was connected to myeloma, how it works in myeloma, and what comes next.
playlist_add
May 16, 2014
mPatient Myeloma Radio: Dr. Paul Richardson, MD, Dana-Farber Cancer Institute
Join us as we talk with Dr. Paul Richardson about why and when patients should join a multiple myeloma clinical trial. As a leader in very large myeloma clinical trials, Dr. Richardson will share studies that are moving the bar in myeloma care.
playlist_add
Apr 28, 2014
mPatient Myeloma Radio: Dr. Pieter Sonneveld, MD, PhD, Erasmus MC
Join us as we talk Dr. Pieter Sonneveld, MD, PhD, who is the Chairman of the European Myeloma Network and Chairman of the HOVON Foundation about advances in myeloma in Europe and throughout the world.
playlist_add
Apr 25, 2014
mPatient Myeloma Radio: Dr. Walter Kuehl, MD, PhD, Cancer Genetics Branch, NCI
Join us as we talk with myeloma genetics expert Dr. Walter Kuehl, MD, PhD of the National Cancer Institute about the progress being made in segmenting and targeting specific approaches for myeloma. Dr. Kuehl has completed deep research on the various pathways affected by these myeloma "subtypes."
playlist_add
Apr 15, 2014
mPatient Myeloma Radio: Dr. Vincent Rajkumar, Mayo Clinic
Join us as we speak with Dr. Vincent Rajkumar, MD of the Mayo Clinic about obesity and race in multiple myeloma.
playlist_add
Apr 11, 2014
mPatient Myeloma Radio: Dr. Jonathan Licht, MD, Robert H. Lurie CCC
Join us as we talk with Dr. Jonathan Licht of the Robert H. Lurie Comprehensive Cancer Center and Northwestern University about high risk myeloma.
playlist_add
Mar 28, 2014
mPatient Myeloma: Dr. Aaron Rapoport, MD, University of Maryland Cancer Ce
Join us as we talk with Dr. Aaron Rapoport, MD of the University of Maryland Greenbaum Cancer Center about his vaccine approaches and T-cell research in myeloma.
playlist_add
Mar 21, 2014
mPatient Myeloma Radio: Dr. Robert Orlowski, MD, PhD, MD Anderson
Join us as we talk with Dr. Robert Z. Orlowski, MD, PhD of MD Anderson Cancer about immunotherapies and the latest in his myeloma research.
playlist_add
Mar 7, 2014
mPatient Radio: Dr. Leif Bergsagel, MD, Mayo Clinic Scottsdale
Join us as we talk with Dr. Leif Bergsagel about his research to subdivide myeloma by genetic type and apply different therapy approaches to these unique variations of myeloma.
playlist_add
Feb 28, 2014
mPatient Radio: Dr. Jens Lohr, Dana Farber Cancer Institute and BROAD Institute
Learn why myeloma is so genetically complicated and the implications this has for personalized medicine in myeloma. Dr. Lohr, MD, PhD of the Dana Farber Cancer Institute and BROAD Institue recently published an article in Cancer Cell describing the complexity and what it means for myeloma patients.
playlist_add
Feb 21, 2014
mPatient Radio: Dr. Phillip McCarthy, Roswell Park Cancer Institute
Listen as we talk with Dr. Phillip McCarthy of the Roswell Park Cancer Institute about his work in immunotherapy, transplantation and myeloma care.
playlist_add
Feb 7, 2014
HealthTree Podcast for Myeloma: Dr. Damian Green, Fred Hutchinson Cancer Center
Join us as we talk with Dr. Damian Green about radiation, radioimmunotherapy and how progress is being made for high-risk patients in myeloma treatment today.
playlist_add
Jan 24, 2014
HealthTree Podcast for Myeloma: Dr. Parameswaran Hari, Med College of Wisconsin
Join us as we talk with Dr. ParameswaranHari, MD, MRCP, MS, about transplants, his latest myeloma research and open clinical trials. Dr. Hari is the Armand Quick-William Stapp Professor of Hematology, Section Head of Hematological Malignancies and the Director of the Adult Blood and Marrow Transplant Program at the Medical College of Wisconsin.
playlist_add
Jan 17, 2014
HealthTree for Multiple Myeloma: Dr. Noopur Raje, Massachusetts General Hospital
Join us as we talk with Dr. Noopur Raje, MD of Massachusetts General Hospital about the research she performs in the Raje Lab to study how the bone marrow environment affects myeloma growth.
playlist_add
Jan 10, 2014
HealthTree for Multiple Myeloma: Dr. Jatin Shah, MD Anderson
Join us as we talk with Dr. Jatin Shah about his many open mutliple myeloma clinical trials at MD Anderson. With a wave of new approaches just presented at ASH, Dr. Shah discusses the wide variety of clinical trial offerings for myeloma patients (from newly diagnosed to relapsed or refractory) that include the use of monoclonal antibodies and other cell signaling inhibitors that are now being tested in the mix with existing therapies.
playlist_add
Nov 8, 2013
HealthTree Podcast for Multiple Myeloma: Dr. Michael Misialek, Newton-Wellesley
What do your lab results mean and how can you learn more about your specific type of multiple myeloma? Dr. Michael J. Misialek, MD tells us that we have a pathologist that is ready and waiting to help you understand your disease.
playlist_add
Nov 1, 2013
HealthTree Podcast for Multiple Myeloma: Dr. Gareth Morgan, ICR
Join us as we speak with Dr. Gareth Morgan from the Institute of Cancer Research as we discuss how we can get to personalized medicine in multiple myeloma.
playlist_add
Oct 18, 2013
HealthTree Podcast for Multiple Myeloma: Dr. Rodger Tiedemann, UHN
Join us to discuss with Dr. Rodger Tiedemann of the Ontario Cancer Institute and the Princess Margaret Hospitel his latest discovery about why myeloma keeps returning even after stem cell and combination therapy.
playlist_add
Oct 11, 2013
HealthTree Podcast for Multiple Myeloma: Dr. Rafael Fonseca, Mayo Scottsdale
Listen to cytogenetics and genomics expert Dr. Rafael Fonseca, MD of the Mayo Clinic in Scottsdale share the latest in his myeloma research and his open clinical trials.
playlist_add
Oct 4, 2013
HealthTree Podcast for Multiple Myeloma: Dr.Frits van Rhee, UAMS
Hear myeloma expert Dr. Frits van Rhee, MD, PhD from the University of Arkansas for Medical Sciences discuss the latest research in Total Therapy and open clinical trials at UAMS.
playlist_add
Sep 27, 2013
HealthTree Podcast for Multiple Myeloma: Dr. Shaji Kumar, Mayo Clinic
Listen to Dr. Shaji Kumar, MD of the Mayo Clinic in Rochester as he describes how all myeloma was once MGUS, how new inhibitors (like CDK and HDAC) work, and his study of how cytogenetics impacts disease progression.
playlist_add
Sep 20, 2013
HealthTree Podcast for Multiple Myeloma: Dr. Sergio Giralt, MSKCC
Listen to our next show with Dr. Sergio Giralt of the Memorial Sloan-Kettering Cancer Center to hear about his deep expertise in transplantation and his latest trials including the use of a vaccine in combination with transplant and a gene-targeted approach using cabozantinib.
playlist_add
Sep 12, 2013
HealthTree Podcast for Multiple Myeloma: Dr. Craig Crews, Crews Lab at Yale U
Listen to Dr. Craig Crews of the Crews Laboratory at Yale University describe how a drug begins as an idea and becomes a real myeloma therapy used in the clinic. He shares his story of the discovery and development of the drug carfilzomib (Kyprolis).
playlist_add
Sep 6, 2013
HealthTree Podcast for Multiple Myeloma: Dr. James R. Berenson, IMBCR
This week on HealthTree Podcast for Multiple Myeloma we welcome Dr. James Berenson of the Institute for Myeloma & Bone Cancer Research (IMBCR) to discuss the latest in his research and his open clinical trials.
playlist_add
Aug 30, 2013
HealthTree Podcast for Multiple Myeloma: Dr. William Bensinger, FHCRC
This week on HealthTree Podcast for Multiple Myeloma, we welcome Dr. William Bensinger of the Fred Hutchinson Cancer Research Center to discuss his research and many trials including a Kyprolis trial. With the recent announcement of Amgen's purchase of Onyx, we will be asking how we can continue to fast-track drug development for multiple myeloma.
playlist_add
Aug 16, 2013
HealthTree Podcast for Multiple Myeloma: Dr. Don Benson The James Ohio State
This week on HealthTree Podcast for Multiple Myeloma we welcome Dr. Don Benson of The James Comprehensive Cancer Center at Ohio State University back to discuss his research in nk cells, immunotherapy, and an upcoming PD-1 trial.
playlist_add
Aug 9, 2013
HealthTree Podcast for Multiple Myeloma: Dr. Robert A. Kyle, Mayo Clinic
This week on HealthTree Podcast for Multiple Myeloma, listen to Dr. Robert A. Kyle, a pioneer in myeloma research, as he gives us perspective on the history of "Innovation in Myeloma" and his lengthy research as the first to identify MGUS and smoldering myeloma.
playlist_add
Aug 2, 2013
HealthTree Podcast for Multiple Myeloma: Dr. C. Ola Landgren, NCI
This week on HealthTree Podcast for Multiple Myeloma, listen to Dr. Landgren as we discuss his research in new therapies for myeloma in its precursor states (MGUS and smoldering), molecular profiling of myeloma and why it is important in predicting progression, and his related research with myeloma and the immune system.
playlist_add
Jul 19, 2013
HealthTree Podcast for Multiple Myeloma: Dr. Don Benson, The James Ohio State
This week on HealthTree Podcast for Multiple Myeloma, listen to the first in a two-part series with Dr. Benson as he gives us a primer in clinical trials. Because only 5% of myeloma patients participate in clinical trials, we want you to know all about them so you can understand why you would want to enroll, how they are staged, who funds them and what you can expect in outcomes.
playlist_add
Jul 12, 2013
HealthTree Podcast for Multiple Myeloma: Dr. Guido Tricot, University of Iowa
This week on HealthTree Podcast for Multiple Myeloma listen to Dr. Guido Tricot discuss his latest research and open clinical trials.
playlist_add
Jul 5, 2013
HealthTree Podcast for Multiple Myeloma: Dr. Robert Z. Orlowski, MD Anderson
This week on HealthTree Podcast for Multiple Myeloma, listen to myeloma pioneer Dr. Robert Z. Orlowski discuss his latest research and open clinical trials in our first patient internet radio interview.
playlist_add